Page 29 - Ace2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A team of scientists from the USA and Canada has recently characterized the antibodies developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in response to an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

A genetic variant of TMPRSS2 may confer protection against severe COVID-19 Among a large sample of coronavirus disease 2019 (COVID-19) patients, researchers found that a genetic variant – caused by an amino acid substitution from valine to methionine – is associated with a reduced chance of severe disease. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, can have a diverse range of effects on people. Some people develop no symptoms; some have mild fever, sore throat, among other symptoms; whereas in others, the infection becomes...

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

Novel host-viral-microbiome interactions during COVID-19 may determine outcome The current pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been spreading rapidly for over a year. Though primarily a respiratory illness, its manifestations are often protean and may be life-threatening. A new preprint on the medRxiv* server discusses how the underlying disease mechanisms are regulated such that the local or mucosal immune response is distinct from the systemic response. Viral suppression of innate but not adaptive ...